Desenvolvimento de nanopartícula híbrida funcionalizada com BSA para potencial uso no tratamento alternativo a resistência a múltiplas drogas (MDR)

Abstract

Cancer is one of the most deadly diseases in the world and one of the main factors related to therapeutic failure is the development of molecular resistance to antineoplastic agents. In view of this and to provide effectiveness in the treatment, nanotechnology can be a promising strategy to improve the performance of the drug, allowing greater selectivity at the site of action and an alternative to resistance to multiple drugs (MDR). The aim of the study was to obtain and characterize hybrid nanoparticles functionalized with BSA (Serum Bovine Albumin) for potential use in the alternative treatment to Multiple Drug Resistance (MDR). Nanoparticles smaller than 200 nm of poly (lactic-co-glycolic acid) (PLGA) and Cholesterol were produced and functionalized with BSA using the nanoprecipitation technique. The development of the formulation and obtaining parameters were optimized by measurements of average particle size, polydispersion index, zeta potential, pH, absorption spectroscopy in the infrared region with fourier transform (FTIR-ATR), incorporation efficiency and studies in vitro. Particles of reduced size (100-200 nm) and with a protein association efficiency of approximately 95% were obtained. The high efficiency of association of the protein and the results of the zeta potential demonstrated that the BSA was adsorbed on the surface of the particle, remaining as a stable colloidal dispersion for 6 weeks. In vitro tests of hemolytic activity and with the 3T3 and RAW cell line demonstrated that the system is viable with BSA functionalization. Therefore, nanoparticles functionalized with BSA have been successfully developed, becoming a promising carrier for binding bioactive molecules and being an alternative to resistance to multiple drugs.